<?xml version="1.0" encoding="UTF-8"?>
<ref id="B26">
 <label>26.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Haasbach</surname>
    <given-names>E</given-names>
   </name>
   <name>
    <surname>Muller</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Ehrhardt</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Schreiber</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>Pleschka</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Ludwig</surname>
    <given-names>S</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>The MEK-inhibitor CI-1040 displays a broad anti-influenza virus activity 
   <italic>in vitro</italic> and provides a prolonged treatment window compared to standard of care 
   <italic>in vivo</italic>
  </article-title>. 
  <source>Antiviral Res</source>. (
  <year>2017</year>) 
  <volume>142</volume>:
  <fpage>178</fpage>â€“
  <lpage>84</lpage>. 
  <pub-id pub-id-type="doi">10.1016/j.antiviral.2017.03.024</pub-id>
  <?supplied-pmid 28377100?>
  <pub-id pub-id-type="pmid">28377100</pub-id>
 </mixed-citation>
</ref>
